Algeciras

This research aims to evaluate whether adding a mobile health mHealth intervention to usual care can improve swallowing difficulties, known as dysphagia, in patients who have had a stroke. Dysphagia after stroke is common and can lead to serious problems like malnutrition, pneumonia, and reduced quality of life. The study is focused on whether using a smartphone or tablet app alongside standard treatment helps patients recover better compared to standard care alone. Participants will be randomly assigned to one of two groups one group will use the mHealth app called DegluApp, which offers personalized nutrition plans, rehabilitation exercises, information, and games to support recovery. The other group will receive conventional care as per healthcare protocols without the app. The study will assess the effects of these approaches over time. Participants will be evaluated at the start and again at 3, 6, and 9 months. Researchers will measure swallowing improvement, including the type of food texture and volume tolerated, as well as perceived quality of life, nutritional status, body measurements, muscle strength, and caregiver burden. Safety and adherence will be monitored, and the total participation spans up to nine months.

Researchers are evaluating the effectiveness and safety of subcutaneous immunotherapy SCIT in people aged 12 to 65 who have allergic rhinitis or rhinoconjunctivitis, with or without mild to moderate asthma. The study focuses on patients sensitized to specific house dust mites, Dermatophagoides pteronyssinus andor Dermatophagoides farinae. This is a phase 3, double-blind, placebo-controlled, randomized trial conducted at multiple centers. Participants will be randomly assigned to one of three groups two receive different doses of SCIT 10,000 TUmL or 30,000 TUmL of allergenic extract, and one receives a placebo injection without active ingredients. Treatment lasts for one year, with doses administered subcutaneously. The study compares the two active treatment groups to the placebo group to determine which dose may be more effective and safe. During the trial, participants will be closely monitored for symptoms and medication use, assessed by the Combined Symptoms and Medication Score CSMS over 12 months. Researchers will also track medication-free days, symptom-free days, quality of life related to asthma and rhinitis, adverse events, and immunological responses. Participants will log symptoms and medication use via smartphone. Safety and treatment effects will be evaluated throughout the study period.

Primary immune thrombocytopenia PIT, formerly called idiopathic thrombocytopenic purpura, is a disease where platelets are destroyed faster than they are made, leading to low platelet counts. The causes are not fully understood, and the disease affects patients differently, making diagnosis based on ruling out other causes. There is limited data on how common PIT is in Spain, so this study aims to better understand the characteristics and treatment of patients with PIT and other immune thrombocytopenias in Spain. This research is an observational, multicenter study collecting information from hospital patient records across Spain. It includes children from 2 months old and adults who have been monitored since 2015 with a diagnosis or suspicion of PIT or similar immune-related thrombocytopenia. The study gathers data on clinical features, lab results, and treatments received, without introducing any new treatments or interventions. Participants medical histories will be reviewed to describe their disease and treatment details. Researchers will analyze clinical and laboratory data from enrollment onwards, comparing it with past published ITP data and evaluating responses to first and subsequent treatments. The study is sponsored by the Fundacin Espaola de Hematologa y Hemoterapia and will continue collecting data until 2034.